The presence of anti-MDA5 antibody is associated with increased 90-day mortality [41] and has been recognized as a strong predictor of poor prognosis in patients with PM-/DM-/CADM-ILD [17,37,38]. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.